Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2031-03-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is relapsed or progressive after standard upfront therapy.
Phase:
PHASE1
Details
Lead Sponsor:
Sabine Mueller, MD, PhD
Treatments:
Bevacizumab Irinotecan Temozolomide Triiodothyronine Vascular Endothelial Growth Factor A